Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir.
|Titolo:||Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores|
|Parole Chiave:||Drug Administration Schedule; HIV Protease Inhibitors; Pyrones; Clinical Trials, Phase III as Topic; Humans; Pyridines; RNA, Viral; HIV-1; Viral Load; Drug Resistance, Viral; Lopinavir; Ritonavir; HIV Infections; Pyrimidinones; Treatment Outcome; Antiretroviral Therapy, Highly Active; HIV Protease; Mutation|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||18-ott-2007|
|Digital Object Identifier (DOI):||10.1097/QAD.0b013e3282ef6db7|
|Appare nelle tipologie:||01 - Articolo su periodico|